In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On an area of 55,000 m2, the park now hosts more than 40 companies and many academic institutions representing a healthy mix of young start-ups and global companies as well as university clinics, institutes, and research groups.
In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with communal infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.
The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.
Kuros Biosciences reports first U.S. & UK sales of MagnetOs Commercial roll-out in the U.S. and Europe on track
Schlieren (Zurich), Switzerland, July 2, 2018 – Kuros Biosciences (SIX: KURN) announced today it recorded the first commercial use last week of MagnetOs in the U.S., and the company expects to ramp up its commercial activities in Europe and the U.S. in the second half of 2018. Joshua M. Ammerman, M.D....
Molecular Partners Appoints Pamela A. Trail as Chief Scientific Officer; Michael T. Stumpp Assumes Role of Chief Operating Officer of the Company
Zurich-Schlieren, June 21, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today the appointment of Pamela A. Trail, Ph.D., as Chief Scientific Officer. Pamela Trail served most recently as Vice President of Oncology Strategy and Program Direction...